Loading…
← CockpitCompetitor Analysis › 1666.HK Tong Ren Tang Technologies Co., Ltd. Class HOpen in the cockpit ↗

Tong Ren Tang Technologies Co., Ltd. Class H1666.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major
Momentum neutral 55
Mkt cap
$491M
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$360,216
20-day average traded
Fwd P/E
7.3×
forward earnings
ROIC−WACC
-1.7 pp
WACC 7.1%
Hurdle
-24 pp
Req g minus delivered
Next earnings
121 days
19 Mar 2027
Close · HKDHK$3.02
1D+0.3%
1W+1.9%
1M-2.7%
3M-7.4%
6M-19.5%
YTD-31.5%
1Y-36.7%
ATR %2.8%
52w lowhigh39.0% off high

What Tong Ren Tang Technologies does

Employees: 3,951

Tong Ren Tang Technologies at a glance

Size Tong Ren Tang Technologies (1666.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $491M, the 750th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.02 on 18 Nov 2026.

Performance Over six months the shares fell 19.5%, against -8.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue fell 13.9% over the last twelve months (peer median +13.0%); the operating margin is 11.6% (peer median 6.8%).

Valuation It trades at 7.3× forward earnings against a peer median of 18.2× (2nd cheapest of 6).

Price implies For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -24 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.7 points below its cost of capital (7.1% WACC).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 921666.HK 81
Six months, rebased to 100: Tong Ren Tang Technologies against the median of its 20 peers (local-currency closes).

Tong Ren Tang Technologies financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$6.45BHK$7.03BHK$7.87BHK$7.48BHK$6.97B
Revenue growth—-11%+5%+7%—
Gross profitHK$2.38BHK$2.63BHK$3.08BHK$3.11BHK$2.99B
EBITDAHK$1.12BHK$1.23BHK$1.38BHK$1.54BHK$1.71B
Net incomeHK$347MHK$430MHK$566MHK$652MHK$678M
Free cash flowHK$1.32BHK$1.63B-HK$78.6MHK$594MHK$703M
Capital expenditureHK$112MHK$140MHK$233MHK$119MHK$201M
Total debtn/aHK$2.42BHK$2.79BHK$1.79BHK$1.79B

Quarterly statements and history in the cockpit →

Tong Ren Tang Technologies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+20%002107AARTIDRUGS301277003090600513TKNO300584003020GYRE688373603207RGNXHNSAGUJTHEM600624INDPSMSPHARMAEGTX1666.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Tong Ren Tang Technologies is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%20×40×AARTIDRUGS003090003020SMSPHARMAEGTX1666.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tong Ren Tang Technologies is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%002107AARTIDRUGS301277300584600222603207HNSA1666.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tong Ren Tang Technologies is the large dot.

Tong Ren Tang Technologies competitors and peer comparison

How Tong Ren Tang Technologies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tong Ren Tang Technologies against its 20 peers (data as of 18 Nov 2026)
Measure1666.HKPeer medianRank in peer set
1-month return-2.7%-0.8%9th lowest of 21
6-month return-19.5%-8.8%9th lowest of 21
Distance from 52-week high-39.0%-35.5%10th lowest of 21
Revenue growth (TTM)-13.9%+13.0%lowest of 20
Operating margin11.6%6.8%6th highest of 20
Forward P/E7.3×18.2×2nd cheapest of 6
Growth the price implies (Req g, 7 yrs)-17.2%5.9%least demanding of 8
Growth delivered (Del g)+6.3%+4.4%4th highest of 8
Hurdle (Req g minus delivered)-23.5 pp+4.3 pp2nd least demanding of 8
ROIC minus cost of capital-1.7 pp-3.0 pp7th highest of 17
EV / EBITDA3.3×19.2×cheapest of 5
Net debt / EBITDA-3.0×1.8×least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%7.3×-17.2%+6.3%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%n/a5.9%-4.1%
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%21.3×22.1%+3.5%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%n/a8.9%+9.1%
Daewoong 003090.KSSouth Korea$495M-28%+6%11%4.1×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%n/an/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%n/an/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%n/a3.3%-1.1%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%18.2×n/an/a
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%n/a16.7%+4.4%
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%n/an/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%n/an/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%n/a-5.4%+7.6%
REGENXBIO RGNXUnited States$480M+22%-5%-120%n/an/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%n/a-4.7%+105.3%
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%n/an/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%n/an/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%42.2×n/an/a
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%n/an/an/a
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%15.1×n/an/a

Questions

Which companies are Tong Ren Tang Technologies's closest peers?
The cockpit's peer set: Shandong Wohua Pharmaceutical (002107.SZ), Aarti Drugs (AARTIDRUGS.NS), Newland Pharmaceutical (301277.SZ), Daewoong (003090.KS), Jiangsu Lianhuan Pharmaceutical (600513.SS), Alpha Teknova (TKNO), Nanjing Hicin Pharmaceutical (300584.SZ), Hefei Lifeon Pharmaceutical (003020.SZ).
Is Tong Ren Tang Technologies expensive compared with its peers?
On forward p/e it trades at 7.3× against a peer median of 18.2×, 2nd cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -24 pp: the price already allows for a slowdown.
How has Tong Ren Tang Technologies stock performed?
Over six months to 18 Nov 2026 the shares returned -19.5% against -8.8% for the median peer; over one year -36.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.